Search Results
151 items found for "Systemic treatment"
- Ep 130 with Dr. Richard Premont
regulation/desensitization of the liver glucagon receptor and glucagon-stimulated adenylyl cyclase system protein-coupled receptor signaling particularly by the G protein-coupled receptor kinase (GRK) – beta-arrestin system regulating cellular signaling pathways, particularly in conjunction with better characterized signaling systems
- Ep 133 with Dr. Richard Premont
regulation/desensitization of the liver glucagon receptor and glucagon-stimulated adenylyl cyclase system protein-coupled receptor signaling particularly by the G protein-coupled receptor kinase (GRK) – beta-arrestin system regulating cellular signaling pathways, particularly in conjunction with better characterized signaling systems
- Ep 131 with Dr. Richard Premont
regulation/desensitization of the liver glucagon receptor and glucagon-stimulated adenylyl cyclase system protein-coupled receptor signaling particularly by the G protein-coupled receptor kinase (GRK) – beta-arrestin system regulating cellular signaling pathways, particularly in conjunction with better characterized signaling systems
- DANGER Signals Activate G-Protein Receptor Kinases Suppressing Neutrophil Function and Predisposing to Infection After Tissue Trauma
Published date May 8, 2023 Abstract "Objective: Surgery injures tissue and predisposes to local and systemic functions (cytoskeletal reorganization, chemotaxis (CTX), phagocytosis, bacterial killing) in cellular systems Predicted rescue therapies were assessed in cell systems and mouse injury-dependent pneumonia models.
- Ep 109 with Dr. Katarina Nemec
Katarina Nemec " I am a pharmacist with an interest in systems pharmacology and precision medicine. data-driven discovery and adopt data science methodology to tackle relevant scientific questions on the systems
- Interplay between G protein-coupled receptors and nanotechnology
This significantly enhances the potency of nanoparticle delivery systems. provide a fundamental platform for developing powerful and safe GPCR-targeted drugs and nanoparticle systems ligands can modulate membrane binding and endocytosis, powerfully improving the efficacy of nanoparticle system
- Ep 142 with Dr Claudia Stäubert
Claudia had a wide-ranging discussion about Claudia's work on metabolites and their effects on the system Claudia, who has an interest in metabolites and their effects on the system, agreed. the difficulty of distinguishing between different compounds and the effect of media on the cellular system possibility of using native cells with optimized media, but Claudia highlighted the complexity of the system
- miR-19a may function as a biomarker of oral squamous cell carcinoma (OSCC) by regulating the signaling pathway of miR-19a/GRK6/GPCRs/PKC in a Chinese population
In this study, we focused on the hygrosensory, and closely related thermosensory, systems in the vinegar mechanisms underlying hygro- and thermosensation may shed light on the broader understanding of sensory systems
- Principles of Pharmacology in Drug Discovery I
process of characterizing the mechanism of action of ligands to enable the prediction of activity in vivo systems comprehensive understanding of the unique science of pharmacology and how it can describe drug action in system-independent
- The pyruvate-GPR31 axis promotes transepithelial dendrite formation in human intestinal dendritic cells
Using human induced pluripotent stem cell-derived cDC1s and a monolayer human gut organoid coculture system Our results highlight the role of GPCRs in tuning the human gut immune system according to local metabolic
- Principles of Pharmacology in Drug Discovery I
process of characterizing the mechanism of action of ligands to enable the prediction of activity in vivo systems comprehensive understanding of the unique science of pharmacology and how it can describe drug action in system-independent
- Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma
Despite advances in the treatment, many patients experience disease relapse or become refractory to treatment Talquetamab, a Food and Drug Administration-approved T-cell-directing bispecific antibody developed for treatment
- Session VII | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
HERE < Back to Full Agenda Session VII Physiological and pathological roles of AGPCRs in the nervous system In vivo expression profiling has shown Remo expression in the central (CNS) and peripheral nervous systems Knowledge of the structural dynamics of this complex is limited and pharmacological and in vivo systems
- NPFF stimulates human ovarian cancer cell invasion by upregulating MMP-9 via ERK1/2 signaling
Treatment of SKOV3 cells with NPFF did not affect cell viability and proliferation but stimulated cell NPFF treatment upregulates matrix metalloproteinase-9 (MMP-9) expression. Our results also showed that ERK1/2 signaling was activated in SKOV3 cells in response to the NPFF treatment
- G protein-coupled receptors: A target for microbial metabolites and a mechanistic link to microbiome-immune-brain interactions
receptors, particularly expressed on human intestinal epithelial cells, immune cells and the nervous system Suzi Hong Tags G protein-coupled receptors , Gut microbiota , Human-microbiota interactions , Immune system
- Unbiased multitissue transcriptomic analysis reveals complex neuroendocrine regulatory networks mediated by spinal cord injury-induced immunodeficiency
motor function in the body below the level of injury, is a devastating disease of the central nervous system SCI-IDS predominantly occurs following injury above the T5 levels and eventually leads to systemic immune Neuraxial nerve inflammation caused by SCI persists indefinitely, blocking nerve repair; persistent system-wide
- Ep 86 with Nicole (Nicki) Perry-Hauser
neuropsychiatric phenotypes, and my work will provide a basis for understanding aGPCR biology in the nervous system
- The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy
emerging therapies and discussing innovative strategies to harness the full potential of GPCR-targeted treatments Carlotta Tacconi, Serena Ranucci, Marco De Giovanni Tags Angiogenesis , Cancer , GPCRs , Immunity , Treatment
- Ep 66 with Dr. Antony A. Boucard Jr
master’s degree in 2000 and a Ph.D. degree in 2003 with a particular interest in the cardiovascular system Motivated by a new ambition to study the nervous system, Dr.
- G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression
Finally, we review the progress of clinical trials of GPCR-targeted drugs for cancer treatment, which may be combined with immunotherapy to improve treatment efficacy.
- Ep 02 with Dr. Terry Hébert
grasp of receptor function in pathophysiological settings with a special interest in the cardiovascular system
- Session VI | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
October 23-25 Download PDF Program HERE < Back to Full Agenda Session VI AGPCRs shaping the nervous system As a clinician, he specializes in surgical treatment of brain tumors.
- Ep 155 with Endocrine Metabolic GPCR Organizers
crosstalk, and applying these mechanisms for distinct GPCRs in diverse physiological and pathophysiological systems Gorvin is a Wellcome Trust & Royal Society Sir Henry Dale Fellow at the Institute of Metabolism and Systems
- Ep 20 with Dr. Jennifer Pluznick
laboratory of Michael Caplan at Yale University, where she studied both renal physiology and sensory biology systems
- Ep 124 with Gáspár Pándy-Szekeres
have branched out to multiple areas of GPCR research such as sequence alignments, generic numbering systems
- Ep 138 with Dr. Daniel Isom
of Medicine in 2016, where he is currently a practicing molecular pharmacologist and biophysicist, systems
- Ep 123 with Dr. Lukas Grätz
have branched out to multiple areas of GPCR research such as sequence alignments, generic numbering systems
- Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation
July 27, 2024 Abstract "Genetic heterogeneity in ovarian cancer indicates the need for personalised treatment antibody-conjugated drugs and drug-loaded nanoparticles, highlighting a neglected potential to develop personalised treatment